All News
Scary Outcomes with Systemic Sclerosis Sine Scleroderma
The hallmark of systemic sclerosis is scleroderma, but less than 10% of SSc patients have sine scleroderma (ssSSc). A EUSTAR database review compared the manifestations and outcomes of ssSSC to limited cutaneous SSc and diffuse cutaneous SSc.
Read Article
Predictors of Cardiovascular Events in ANCA-Associated Vasculitis
A large, retrospective, multinational study of patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) shows they may be at risk for cardiovascular events (CVEs).
Read Article
Check SSc-ILD Patients on Nintedinib for Malnutrition
MedPage Today
During nintedanib treatment for interstitial lung disease associated with systemic sclerosis (SSc-ILD), clinicians prescribing the drug should be watchful for an unusual, indirect side effect, trial data suggested.
Read Article
EULAR 2023 – Day 3 Report
Day 3 was a sunny warm day in Milan at the 2023 EULAR Congress meeting. Here are a few of my favorite abstracts from today.
Read Article
Check SSc-ILD Patients on Nintedinib for Malnutrition
During nintedanib treatment for interstitial lung disease associated with SSc-ILD, clinicians prescribing the drug should be watchful for an unusual, indirect side effect, trial data suggested.
https://t.co/TmN71qSCb2 https://t.co/TVU2qcPdZE
Links:
Dr. John Cush RheumNow ( View Tweet)
Predictors of Cardiovascular Events in ANCA-Associated Vasculitis
A large, retrospective, multinational study of patients with ANCA-AAV shows they may be at risk for CVEs.
https://t.co/k9XPolEXKc https://t.co/0nxai3Eqe2
Links:
Dr. John Cush RheumNow ( View Tweet)
Check SSc-ILD Patients on Nintedinib for Malnutrition
During nintedanib treatment for interstitial lung disease associated with SSc-ILD, clinicians prescribing the drug should be watchful for an unusual, indirect side effect, trial data suggested.
https://t.co/5Q3xCwLvPa https://t.co/mGD3DCYZR0
Links:
Dr. John Cush RheumNow ( View Tweet)
JAKi in Rheumatoid Arthritis: Cancer and Cardiovascular Risks
Dr. Antoni Chan discusses abstracts OP0132, POS0831, and OP0133 presented at EULAR 2023 in Milan, Italy.
https://t.co/ApLaPf7uKP https://t.co/nbZgwIlHyb
Links:
Dr. John Cush RheumNow ( View Tweet)
Among 247.3 million US adults. 10.0% (20.3 million) had CVD & 56% were at risk for CVD. Yet only 3.6 million CVD (18%) & 34.5 million at risk for CVD (26%) used wearable devices (compared to 29% in US adults, but less than half wear every day. https://t.co/04xqtkw61x https://t.co/ETTjamvHi2
Links:
Dr. John Cush RheumNow ( View Tweet)
CV and Cancer Risk with JAK inhibitors
Dr. Jonathan Kay discusses abstract OP0132 presented at EULAR 2023 in Milan, Italy.
https://t.co/SZLohnNEa1 https://t.co/ZEv0Q2NSBf
Links:
Dr. John Cush RheumNow ( View Tweet)
Watch: SpA and Interstitial Lung Disease
Dr. Eric Ruderman discusses abstract OP0006 presented at EULAR 2023 in Milan, Italy.
https://t.co/wsR3gv1jSr https://t.co/ULYbJeoFHi
Links:
Dr. John Cush RheumNow ( View Tweet)
An update on JAK inhibitors and cardiovascular risks
Dr. Antoni Chan ( @synovialjoints ) shares #EULAR23 developments on JAK/TYK2 inhibitors.
https://t.co/VovWE2OuXW https://t.co/QXKZLh5RuK
Links:
Dr. John Cush RheumNow ( View Tweet)
Depositions of crystals in coronary arteries were associated with MACE @rheumnow #EULAR2023 https://t.co/VHxtsB7ZsA
Bella Mehta bella_mehta ( View Tweet)
The incidence of MACEs at 8 years is low in AS patients treated with NSAIDs. Study of 22929 patients, NSAIDs (SHR: 0.40 [0.32-0.49], p<0.001) and anti-TNFs (SHR: 0.61 [0.47-0.81], p<0.001) associated with a lower risk of MACE, Fakih O, Abst#POS0301, #EULAR2023 @RheumNow https://t.co/i5GZMcJwyO
Dr. Antoni Chan synovialjoints ( View Tweet)
MmF and Tacrolimus both work in systemic sclerosis with ILD. @RheumNow #EULAR2023 https://t.co/Ro6AjP3nij
Bella Mehta bella_mehta ( View Tweet)
#EULAR2023 Clinical Highlights. CTD: OP0240 Open label study (N=26) showed stabilisation/improvement in FVC in patients with #ILD treated either Tacrolimus vs MMF. No efficacy difference between both therapies @RheumNow https://t.co/d3rCzNgYHK
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
ILD in RA and PsA
@AurelieRheumo discusses inconsistent data inconsistent data have proposed on the effect of bio/tsDMARDs on the risk of ILD.
ILD is a severe extra articular manifestation of RA, with limited treatment strategies and poor prognosis.
https://t.co/U1RjvgTCL8 https://t.co/qmxXBTK05N
Links:
Dr. John Cush RheumNow ( View Tweet)
Predictors of myocarditis in anti-synthetase syndome - 43 pta 30% with myocarditis. More frequently males with high troponin levels. Only fever was more frequently observed in myocarditis pts. Pos1224 @rheumnow #EULAR2023
Bella Mehta bella_mehta ( View Tweet)
Should we use #immunesuppression EARLY in #scleroderma to prevent #ILD? Answer from a study comparing Y vs N immune suppression- there was no difference in FVC decline. Maybe not a long enough study, ? Chanelling bias scleroderma #lung #disease OP0239 @RheumNow #EULAR2023
Janet Pope Janetbirdope ( View Tweet)
Can’t escape ORAL Surveillance RCT talk
Lots of real world data on CV risk & JAKi here
(with all the selection, measurement bias)
First up: multinational JAK-pot study (n=>50k)
Even if you mirror the high-risk RCT cohort - not much there for MACE
OP0219 #EULAR2023 @RheumNow https://t.co/FfNspdivri
David Liew drdavidliew ( View Tweet)
